ANI Pharmaceuticals, Inc. (ANIP)
Largest Insider Buys in Sector
ANIP Stock Price History Chart
ANIP Stock Performance
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through …
Insider Activity of ANI Pharmaceuticals, Inc.
Over the last 12 months, insiders at ANI Pharmaceuticals, Inc. have bought $0 and sold $38.77M worth of ANI Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at ANI Pharmaceuticals, Inc. have bought $562,034 and sold $29.25M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,224 shares for transaction amount of $199,997 was made by Lalwani Nikhil (PRESIDENT & CEO) on 2022‑03‑21.
List of Insider Buy and Sell Transactions, ANI Pharmaceuticals, Inc.
| 2024-10-14 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $57.19 | $14,298 | +0.52% | ||
| 2024-09-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $56.82 | $14,205 | +0.08% | ||
| 2024-08-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $59.62 | $14,905 | 0.00% | ||
| 2024-07-18 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 2,743 0.0132% | $62.00 | $170,066 | -2.75% | ||
| 2024-07-17 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 14,257 0.0682% | $63.16 | $900,472 | -5.26% | ||
| 2024-07-16 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 22,000 0.103% | $64.27 | $1.41M | -7.08% | ||
| 2024-07-15 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 11,000 0.0508% | $63.38 | $697,180 | 0.00% | ||
| 2024-07-12 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $64.91 | $16,228 | 0.00% | ||
| 2024-07-01 | Sale | SVP - CORP. DEV. & STRATEGY | 20,000 0.0924% | $63.44 | $1.27M | 0.00% | ||
| 2024-06-21 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 20,000 0.0866% | $58.90 | $1.18M | +2.65% | ||
| 2024-06-20 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 11,447 0.0503% | $59.86 | $685,217 | +1.15% | ||
| 2024-06-18 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 10,607 0.0474% | $60.76 | $644,481 | -1.12% | ||
| 2024-06-17 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 7,946 0.0359% | $61.41 | $487,964 | -2.77% | ||
| 2024-06-13 | Sale | SR. VP, GENERAL COUNSEL & SEC. | 250 0.0012% | $63.80 | $15,950 | -4.97% | ||
| 2024-06-05 | Sale | SVP, GENERICS | 2,985 0.0142% | $67.00 | $199,995 | -9.69% | ||
| 2024-06-04 | Sale | SVP & CFO | 5,000 0.0234% | $63.58 | $317,900 | -6.55% | ||
| 2024-06-03 | Sale | SVP - CORP. DEV. & STRATEGY | 20,000 0.0969% | $64.41 | $1.29M | -4.72% | ||
| 2024-05-21 | Sale | HEAD OF RARE DISEASE | 2,000 0.0095% | $61.61 | $123,220 | -1.38% | ||
| 2024-05-20 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 12,855 0.0614% | $61.81 | $794,568 | -1.05% | ||
| 2024-05-17 | Sale | HEAD OF R&D, COO-NOVITIUM OPS | 5,836 0.0269% | $62.09 | $362,357 | -0.64% |
Insider Historical Profitability
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | 632620 3.0082% | $58.14 | 1 | 56 | +24.75% |
| Lalwani Nikhil | PRESIDENT & CEO | 377505 1.7951% | $58.14 | 1 | 5 | +31.46% |
| Gassert Chad | SVP - CORP. DEV. & STRATEGY | 193226 0.9188% | $58.14 | 1 | 10 | +29.72% |
| Pera Antonio R | director | 26627 0.1266% | $58.14 | 1 | 2 | <0.0001% |
| MORGENSTERN VICTOR A | director | 455571 2.1663% | $58.14 | 2 | 0 | +243.13% |
Institutional Investor Ownership
| BlackRock | $174.99M | 12.08 | 2.53M | +0.26% | +$445,888.50 | <0.01 | |
| The Vanguard Group | $90.31M | 6.23 | 1.31M | +1.35% | +$1.21M | <0.01 | |
| Helm Capital Management LLC | $66.26M | 4.57 | 958,533 | -14.8% | -$11.51M | 1.96 | |
| Deep Track Capital Lp | $56.82M | 3.92 | 822,001 | +37% | +$15.35M | 0.26 | |
| Dimensional Fund Advisors | $42.11M | 2.91 | 609,173 | +2.95% | +$1.21M | 0.01 |